Update from Japan: Helping the Vaccine-Injured with Dr. Kevin McCairn and Patient Jack Howard

Neuroscientist Dr. Kevin McCairn joins us for our 4th update on a promising treatment for those disabled from the COVID shots. He and Dr. Cato have now treated more than 65 patients with severe injuries, and tonight, one of my patients, 22-year-old Jack and his mother Karrie, share their experience and Jack’s response to the 4-week protocol he went through in Japan. The core protocol combines immune-adsorption apheresis (DFPP), performed through a central line, with daily IV high-dose stem-cell growth factors. The team aims for four weekly cycles of five treatment days. A central line, rather than a peripheral IV, is used because filtering blood closer to the brain more efficiently removes autoantibodies and protein aggregates that impair circulation and oxygen delivery. Growth factors appear synergistic, helping the body recover after the filtration step. Results have been better than he anticipated, given the severity and duration of these patients’ symptoms. Roughly ten to twelve patients showed little improvement, often in the presence of other illnesses. Another group improved only modestly; many of them were later found to have previously undetected cerebrospinal-fluid leaks. A sizable remainder, including Jack, experienced marked relief. McCairn described the overall pattern as encouraging yet still early, noting that some patients may need repeat sessions months or years later. Jack’s account illustrated both the severity of symptoms and the speed of change after treatment. Once an active teenager, he developed unexplained depression, crushing fatigue, abdominal pain, extreme weight swings, swollen purple extremities, and blood-work anomalies that conventional labs could not reconcile. Cardiac imaging was abnormal. Multiple physicians prescribed antidepressants, suggested drug use or infection, or diagnosed conditions later ruled out. After years of emergency-room visits and specialist referrals, the family traveled to Japan in July for a 28-day course. The first two weeks were physically and emotionally taxing, especially the placement of neck catheters. By the third cycle Jack walked thousands of steps and reported returning energy and clearer thinking. Back home he has lost more than thirty pounds of inflammatory swelling, resumed light exercise, and maintains a largely carnivore diet; even one processed meal produced two days of relapse. His mother Karrie emphasized that diet and completion of the full protocol mattered. She also stressed the value of an accompanying advocate, given language barriers and the intensity of daily procedures. McCairn and the family contrasted Japan’s established use of these techniques for neurological conditions with the regulatory, legal, and insurance obstacles that keep similar care scarce in the United States. Screening now includes myelography because CSF leaks appear far more often in this cohort than in the general population and seem to blunt treatment response. Dr. McCairn has been inundated with requests for help but is limited by equipment that cannot process samples quickly and is in need of funds for better analytic equipment to study blood samples systematically. He has instructions on how to send a sample on his website , but due to demand, results could take months. While Jack’s recovery is evidence that targeted intervention can help some of the most severely affected patients, larger studies, longer follow-up, and regulatory change would be required before such care could become routine. Get full access to Dangerous Misinformation at drbowden.substack.com/subscribe